DrugPatentWatch Database Preview
Belatacept - Biologic Drug Details
Email this page to a colleague
» See Plans and PricingSummary for belatacept
| Tradenames: | 1 |
| Patents: | 21 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for belatacept |
Recent Clinical Trials for belatacept
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Massachusetts General Hospital | Phase 4 |
| CareDx | Phase 4 |
| Nantes University Hospital | Phase 2 |
Pharmacology for belatacept
| Mechanism of Action | CD80-directed Antibody Interactions CD86-directed Antibody Interactions |
| Physiological Effect | T Lymphocyte Costimulation Activity Blockade |
Patent Text Search: US Patents for belatacept
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | Perle Bioscience, Inc. (Atlanta, GA) | 2032-09-27 | RX | search | |
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | Bristol-Myers Squibb Company (Princeton, NJ) Domantis Limited (Brentford, Middlesex, GB) | 2031-10-13 | RX | search | |
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | Momenta Pharmaceuticals, Inc. (Cambridge, MA) | 2039-02-26 | RX | search | |
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | Amplimmune, Inc. (Gaithersburg, MD) | 2029-08-31 | RX | search | |
| Bristol Myers Squibb | NULOJIX | belatacept | INJECTABLE; INJECTION | 125288 | 001 | 2011-06-15 | Start Trial | ALS THERAPY DEVELOPMENT INSTITUTE (Cambridge, MA) | 2028-12-05 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for belatacept
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| India | 2764DEN2012 | Start Trial |
| European Patent Office | 2809350 | Start Trial |
| Australia | 2012229236 | Start Trial |
| European Patent Office | 2968549 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2012125569 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for belatacept
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0053 | France | Start Trial | PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001-002 20110617 |
| 90038-8 | Sweden | Start Trial | PRODUCT NAME: BELATACEPT; REG. NO/DATE: EU/1/11/694/001-002 20110617 |
| 00509 | Netherlands | Start Trial | PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - 002 20110617 |
| 2011014,C1248802 | Lithuania | Start Trial | PRODUCT NAME: BELATACEPTUM; REGISTRATION NO/DATE: EU/1/11/694/001, 2011 06 17 EU/1/11/694/002 20110617 |
| 1248802/01 | Switzerland | Start Trial | PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: SWISSMEDIC 61521 15.12.2011 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
